Articles Referencing KYTH
Bearish MACD for Kythera Biopharmaceuticals Inc. - Tale of the Tape
4/24/2013, 12:14 pm from Zacks.com in Investing, Investing Ideas, Stocks
Kythera Biopharmaceuticals Inc. 's ( KYTH ) MACD indicator
has moved into bearish territory with a reading of -0.1667. The
Zacks Rank #4 ("Sell") stock decreased more than 2.85%... Read >>
Gilead Hits 52-Week High - Analyst Blog
3/13/2013, 10:12 am from Zacks.com in Investing, Business, Stocks
Shares of Gilead Sciences, Inc. ( GILD ) hit a 52-week
high of $46.37 on Mar 12. The announcement of impressive fourth
quarter 2012 earnings results and upbeat sales guidance last... Read >>
CBST Gets Global Rights to Antibiotic Candidate - Analyst Blog
3/12/2013, 6:12 pm from Zacks.com in Investing, Business, Stocks
Cubist Pharmaceuticals, Inc. ( CBST ) recently inked
a deal with Japanese company Astellas Pharma Inc.
( ALPMY ) to
acquire the remaining rights of ceftolozane from the... Read >>
Encouraging Data Presented by Gilead - Analyst Blog
3/12/2013, 2:31 pm from Zacks.com in Investing, Business, Stocks
Gilead Sciences, Inc. ( GILD ) recently
presented encouraging data on its chronic angina drug Ranexa
(ranolazine) from a phase IV study (TERISA: n=927). The TERISA
(Type 2 Diabetes... Read >>
Good News for Gilead's HIV Pipeline - Analyst Blog
3/7/2013, 1:40 pm from Zacks.com in Investing, Business, Stocks
Gilead Sciences, Inc. ( GILD ) recently
announced encouraging detailed 24-week data from a phase II study
(study 102) on its HIV single tablet regimen (STR). The STR
includes tenofovir... Read >>
Celgene's Apremilast Encourages - Analyst Blog
3/4/2013, 1:30 pm from Zacks.com in Investing, Business, Stocks
Recently, Celgene Corporation ( CELG ) announced
positive results on its candidate apremilast from a phase III study
(ESTEEM 1), which evaluated patients suffering from
moderate-to-severe... Read >>
Medivation Beats 4Q Expectations - Analyst Blog
3/1/2013, 9:00 am from Zacks.com in Investing, Business, Stocks
Medivation Inc. ( MDVN ) reported a
fourth-quarter loss of 43 cents per share, narrower than the Zacks
Consensus Estimate of a loss of 51 cents per share but well above
the year-ago loss of... Read >>
Bayer Presents Positive ATX101 Data - Analyst Blog
2/5/2013, 5:20 pm from Zacks.com in Investing, Business, Stocks
Bayer AG ( BAYRY ) recently
presented results from two European phase III studies on ATX-101.
ATX-101 is being developed for the reduction of unwanted fat
deposits under the chin known as... Read >>
KYTHERA Biopharma prices upsized deal at $16, at high end of the range
10/11/2012, 8:36 am from Renaissance Capital in News Headlines, IPOs
KYTHERA Biopharmaceuticals, which is commercializing an
injectable treatment for double chins with Bayer, raised $70
million by offering 4.4 million shares at $16, at high end of the
range of... Read >>
Shutterstock prices IPO at $17, above the range
10/10/2012, 10:16 pm from Renaissance Capital in News Headlines, IPOs
Shutterstock, an online marketplace for royalty-free images and
videos, raised $77 million by offering 4.5 million shares at $17,
above the range of $13 to $15. Shutterstock plans to list on... Read >>
KYTHERA Biopharma sets terms for $60 million IPO
9/24/2012, 5:33 pm from Renaissance Capital in News Headlines, IPOs
KYTHERA Biopharmaceuticals, a biotech developing an injection to
reduce fat around the chin, announced terms for its IPO on Monday.
The Calabasas, CA-based company plans to raise $60 million... Read >>
Confidential US filings becoming frequent stop on IPO road
8/24/2012, 6:08 pm from Renaissance Capital in News Headlines, IPOs
Since LegalZoom.com ( LGZ ) became the first
company to publicly file on May 11 after working through a
confidential submission with the SEC, there have been 11 additional
companies to do so,... Read >>